Juan P. Frías

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

Thomas A. Wadden, Timothy S. Bailey, Liana K. Billings et al. · JAMA · 2021 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021 · 1K citations

Medicine, Pharmacology, Pharmacotherapy +16

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 966 citations

Pharmacy, Pharmacology, Pharmacotherapy +17